Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy

Canadian Journal of Physiology and Pharmacology

Volumn 82, Issue 7, 2004, Pages 431-437

  Jia, William W G ^a,b   Bu, Xuexian ^a,d   Philips, Don ^b   Yan, Hang ^a,d   Liu, Guoyu ^a,d   Chen, Xiaoguang ^c   Bush, Jason A ^a   Li, Gang ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d Panagin Pharmaceuticals Inc   (Canada)

Author keywords

Cancer; Chemotherapy; Ginsenosides; Paclitaxel; Synergy

Indexed keywords

3 O BETA DEXTRO GLUCOPYRANOSYL DAMMAR 24 EN 3BETA, 12BETA, 20 TRIOL; CASPASE; CASPASE 3; GINSENG EXTRACT; GINSENOSIDE; IMMUNEX; MITOXANTRONE; PACLITAXEL; PROTEIN P53; RH 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GINSENOSIDES; HUMANS; MICE; MICE, INBRED C57BL; MITOXANTRONE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; PANAX; PLANT EXTRACTS; RECEPTORS, GLUCOCORTICOID; TUMOR SUPPRESSOR PROTEIN P53;

EID: 6344294207     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y04-049     Document Type: Article

References (21)

1. Baker, F., Spitzer, G., Ajani, J., Brock, W., Lukeman, J., Pathak, S., et al. Drug and radiation sensitivity mesasurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium. Cancer Res. 46: 1263-1274.
2. Cai, Z., Capoulade, C., Moyret, L.C., Amor, G.M., Feunteun, J., Larsen, A.K., et al. 1997. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene, 15: 2817-2826.
3. Duda, R.B., Zhong, Y., Navas, V., Li, M.Z., Toy, B.R., and Alavarez, J.G. 1999. American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J. Surg. Oncol. 72: 230-239.
4. Fan, S., Smith, M.L., Rivet, D.N., Duba, D., Zhan, Q., Kohn, K.W., et al. 1995. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55: 1649-1654.
5. Garcia, C.M., Peterson, E.P., Leiting, B., Ruel, R., Nicholson, D.W., and Thornberry, N.A. 1998. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 273: 32608-32613.
6. Hasegawa, H., Matsumiya, S., Murakami, C., Kurokawa, T., Kasai, R., Ishibashi, S., et al. 1994. Interactions of ginseng extract, ginseng separated fractions, and some triterpenoid saponins with glucose transporters in sheep erythrocytes. Planta Med. 60: 153-157.
7. Hasegawa, H., Sung, J.H., Matsumiya, S., Uchiyama, M., Inouye, Y., Kasai, R., et al. 1995. Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids. Planta Med. 61: 409-413.
8. Janicke, R., Sprengart, M., Wati, M., and Porter, A. 1998. Caspase-3 is required for DNA fragmentation and Morphological changes associated with apoptosis. J. Biol. Chem. 273: 9357-9360.
9. Kikuchi, Y., Sasa, H., Kita, T., Hirata, J., Tode, T., and Nagata, I. 1991. Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs, 2: 63-67.
10. Kim, H.E., Oh, J.H., Lee, S.K., and Oh, Y.J. 1999. Ginsenoside RH-2 induces apoptotic cell death in rat C6 glioma via a reactive oxygen- and caspase-dependent but Bcl-X(L)-independent pathway. Life Sci. 65: PL33-PL40.
11. Lee, K.Y., Park, J.A., Chung, E., Lee, Y.H., Kim, S.I., and Lee, S.K. 1996. Ginsenoside-Rh2 blocks the cell cycle of SK-HEP-1 cells at the G1/S boundary by selectively inducing the protein expression of p27kip1. Cancer Lett. 110: 193-200.
12. Leonessa, F., Green, D., Licht, T., Wright, A., Wingate, L.K., Lippman, J., et al. 1996 MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br. J. Cancer 73: 154-161.
13. Nakata, H., Kikuchi, Y., Tode, T., Hirata, J., Kita, T., Ishii, K., et al. 1998. Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn. J. Cancer Res. 89: 733-740.
14. Oh, M., Choi, Y.H., Choi, S., Chung, H., Kim, K., Kim, S.I., et al. 1999. Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int. J. Oncol. 14: 869-875.
15. Ong, Y.C., and Yong, E.L. 2000. Panax (ginseng)- panacea or placebo? Molecular and cellular basis of its pharmacological activity. Ann. Acad. Med. (Singapore) 29: 42-46.
16. Ota, T., Maeda, M., Odashima, S., Ninomiya, T.J., and Tatsuka, M. 1997. G1 phase-specific suppression of the Cdk2 activity by ginsenoside Rh2 in cultured murine cells. Life Sci. 60: PL39-PL44.
17. Park, J.A., Kim, K.W., Kim, S.I., and Lee, S.K. 1998. Caspase 3 specifically cleaves p21WAF1/CIP1 in the earlier stage of apoptosis in SK-HEP-1 human hepatoma cells. Eur. J. Biochem. 257: 242-248.
18. Park, J.A., Lee, K.Y., Oh, Y.J., Kim, K.W., and Lee, S.K. 1997. Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis. Cancer Lett. 121: 73-81.
19. Rui, H. 1997. Research and development of cancer chemopreventive agents in China. J. Cell Biochem. 27(Suppl): 7-11.
20. Xiaoguang, C., Hongyan, L., Xiaohong, L., Zhaodi, F., Yan, L., Lihua, T., and Rui, H. 1998. Cancer chemopreventive and therapeutic activities of red ginseng. J. Ethnopharmacol. 60: 71-78.
21. Yun, T.K. 1999. Update from Asia. Asian studies on cancer chemoprevention, Ann. N.Y Acad. Sci. 889: 157-192.